期刊文献+

肿瘤型 M2丙酮酸激酶在膀胱癌中的表达及临床意义

Expression of Tumor-type M2-pyruvate Kinase in Patients with Bladder Cancer and Its Clinical Significance
下载PDF
导出
摘要 【目的】探讨肿瘤型M2丙酮酸激酶(TumortypeM2-pyruvatekinase,TUM2-PK)在膀胱癌中的表达及临床意义分析。【方法】采取2009年1月至2012年1月,221例膀胱癌患者和220例健康正常人的血清标本,应用酶联免疫吸附测定法(ELISA)定量检测标本的TUM2-PK水平,研究试验组与对照组,以及病理分型与TUM2-PK关系。【结果】膀胱癌患者血清中TUM2-PK的含量明显高于正常对照组[(39.4±3.5)u/mLvs(7.3±2.1)u/mL(P<0.05)];同时根据膀胱癌病理分级TUM2-PK的含量存在一定差异:T1期(32.1±6.1)u/mL,T2期(34.1±4.3)u/mL,T3期(68.2±5.9)u/mL。T1期膀胱癌与T2期膀胱癌TUM2-PK含量无明显差异,但T3期较T1、T2明显增高。【结论】监测血清中TUM2-PK含量有助于膀胱肿瘤的早期诊断,同时根据TUM2-PK的含量亦可作为监测肿瘤及疾病分级的重要手段之一。 [Objective]To explore the expression of tumor type M2-pyruvate kinase(Tu M2-PK) in bladder cancer and its clinical significance .[Methods] Serum samples of 221 patients with bladder cancer and 220 healthy normal people from Jan .2009 to Jan .2012 were collected .Serum level of Tu M2-PK was detected by ELISA ,and compared between experimental group and control group .The correlation between Tu M2-PK and pathological type was analyzed .[Results]Serum levels of Tu M2-PK in patients with bladder cancer were ob-viously higher than those in control group[(39 .4 ± 3 .5)u/mL vs (7 .3 ± 2 .1)u/mL ,P 〈0 .05)] .There was significant difference in Tu M2-PK level among different pathological stages of bladder cancer .Tu M2-PK lev-els in stage T1 ,T2 and T3 were (32 .1 ± 6 .1)u/mL ,(34 .1 ± 4 .3)u/mL and (68 .2 ± 5 .9)u/mL ,respectively . There was no significant difference in Tu M2-PK level between stage T1 and stage T2 .Compared with stage T1 and T2 ,Tu M2-PK levels in stage T3 were increased obviously .[Conclusion] The monitoring of serum Tu M2-PK is helpful for the early diagnosis of bladder cancer .Meanwhile Tu M2-PK level can be also used as an important means for the monitoring and grading of the tumor .
出处 《医学临床研究》 CAS 2014年第4期644-645,648,共3页 Journal of Clinical Research
基金 黑龙江省卫生厅支撑项目(项目编号:2006137)
关键词 膀胱肿瘤/病理学 丙酮酸激酶 Urinary Bladder Neoplasms/PA Pyruvate Kinase
  • 相关文献

参考文献5

二级参考文献51

  • 1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 2Ogata Y, Torigoe S, Matono K, et al. Prognostic factors after potentially curative resection in stage Ⅱ or Ⅲ colon cancer [J]. Kurume Med J, 2005, 52(3): 67-71.
  • 3Caricato M, Borzomati D, Ausania F, et al. Prognostic factors after surgery for locally recurrent rectal cancer: an overview[J]. Eur J Surg Oncol, 2006, 32(2): 126-32.
  • 4Leporrier J, Maurel J, Chiche L, et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer[J]. Br J Surg, 2006, 93(4): 465-74.
  • 5Hardt PD, Ngoumou BK, Rupp J, et al. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer[J]. Anticancer Res, 2000, 20(6D): 4965-8.
  • 6Schneider J, Bitterlich N, Schulze G. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK [J]. Anticancer Res, 2005, 25(3A): 1507-15.
  • 7Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer[J]. Br J Cancer, 2004, 91(5): 980-4.
  • 8Ewald N, Toepler M, Akinci A, et al. Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data[J]. Z Gastroenterol, 2005, 43 (12): 1313 -7.
  • 9Koss K, Maxton D. The potential use of fecal dimeric M2 pyruvate kinase(tumor M2-PK) in screening for colorectal cancer [J]. Gut, 2005, 2: 20.
  • 10Naumann M, Schaum B, Oremek GM, et al. Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study[J]. Dtsch Med Wochenschr, 2004, 129(34-35): 1806-7.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部